Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report
Yong Zhang(Sun Yat-sen University), Guiyun Cui(Xuzhou Medical College), Shenghua Zong(Kingmed Diagnostics), Ming Shi(Southwest Jiaotong University), Hao Chen(Icahn School of Medicine at Mount Sinai), Xue Du(Xuzhou Medical College), Jiang Cao(Xuzhou Medical College), Ying Sheng(Vanderbilt University), Sha liu(Xuzhou Medical College), Junnian Zheng(Xuzhou Medical College), Shenyang Zhang(Xuzhou Medical College), Dan Liu(Florida State University), Gang Wang(Jiangsu University), Wei Zhang(Fudan University), Wan Zhang(Dalian University of Technology), Xiaoyu Huang(Xuzhou Medical College), Xiaopeng Wang(Hebei Medical University), Wenqing Meng(Xuzhou Medical College), Tiancheng Luo(Sun Yat-sen University), Huizhong Li(Jiangsu University), Mingjin Yang(Xuzhou Medical College), Zhouao Zhang(Xuzhou Medical College), Zhouyi Wang(Central South University)
Cited by 28
Related Papers
1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study
|The Lancet|2021|1.1k
CGCG clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2016|650
Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders
|Journal of Allergy and Clinical Immunology|2016|282